combination therapy

Wool heart
Biotech

Don't count out Alnylam's next-gen silencer in ATTR-CM: analysts

Patients' disease stage, transthyretin knockdown levels and trial design have become focal points in debates around silencer-stabilizer combos.
Exelixis

Exelixis’ Cabometyx successor misses primary endpoint in CRC trial

Jun 22, 2026 3:40pm
dart board miss failure
Favicon Fierce Pharma

Merck's Welireg surprisingly fails in first-line kidney cancer

Apr 21, 2026 10:00am
JNJ
Favicon Fierce Pharma

ASH: J&J pressures CAR-T with Tecvayli combo in 2L myeloma

Dec 9, 2025 7:30am
Illustration connected puzzle pieces with the acronym MA

Ipsen inks €1B buyout of French biotech ImCheck

Oct 22, 2025 10:33am
ChatGPT said Low-poly magenta liver model centered on a pale blue background patterned with sketchy dollar signs suggestin
Favicon Fierce Pharma

Big Pharma bets big on MASH with a new combo playbook

Oct 17, 2025 9:30am